Tag: meeting

Orrön Energy AB (“Orrön Energy” or “the Company”) is pleased to announce that it has entered into an agreement with Cloudberry Clean Energy ASA (“Cloudberry”) to combine the Company’s Nordic renewable energy platform and organisation, excluding the Karskruv windfarm, with Cloudberry (the “Transaction”), creating a leading Nordic independent power producer (“IPP”). As consideration for the Transaction, Orrön Energy will receive 27.01 percent of the shares in the enlarged Cloudberry, becoming its largest shareholder. In addition, loan balances and accrued interest of approximately MEUR 93 as of year-end 2025 will be settled or assumed by Cloudberry, and Orrön Energy will receive MEUR 4.2 in cash. Orrön Energy will take an active role in Cloudberry’s future growth through Board representation, bringing Orrön Energy’s and the Lundin Group’s experience of value creation into the combined entity. Orrön Energy will continue to own the Karskruv windfarm and its large-scale European development business, consisting of data centres, solar and battery projects.

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4^th floor, 75013 Paris, France.

To Nasdaq Copenhagen A/S                                                                             25^th June 2026

Paris, June 25, 2026

Louvain-La-Neuve, Belgium, June 25, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Fundação Severino Sombra (FUSVE), a non-profit philanthropic healthcare and educational institution responsible for the University of Vassouras and Hospital Mário Kroeff, for the purchase of a Proteus^®ONE¹ system.